Adaptive enrichment designs for clinical trials may include rules that use interim data to
identify treatment-sensitive patient subgroups, select or compare treatments, or change entry …

A popular design for clinical trials assessing targeted therapies is the two‐stage adaptive
enrichment design with recruitment in stage 2 limited to a biomarker‐defined subgroup …

Two illustrative applications are presented of Bayesian clinical trial designs that make
adaptive subgroup-specific decisions based on elicited utilities of patient outcomes to …

<? show [AQ ID= GQ2 POS=-18pt]?><? show [AQ ID= GQ4]?><? show [AQ ID= GQ5 POS=
12pt]?> In single-arm trials with a predefined subgroup based on baseline biomarkers, it is …

In the precision medicine era,(prespecified) subgroup analyses are an integral part of
clinical trials. Incorporating multiple populations and hypotheses in the design and analysis …

Group sequential design (GSD) is widely used in clinical trials in which correlated tests of
multiple hypotheses are used. Multiple primary objectives resulting in tests with known …

We study the problem of adaptively identifying patient subpopulations that benefit from a
given treatment during a confirmatory clinical trial. This type of adaptive clinical trial has …

The two‐stage preference design (TSPD) enables inference for treatment efficacy while
allowing for incorporation of patient preference to treatment. It can provide unbiased …

A Bayesian group sequential design is proposed that performs survival comparisons within
patient subgroups in randomized trials where treatment–subgroup interactions may be …

Adaptive enrichment designs offer an efficient and flexible way to demonstrate the efficacy of
a treatment in a clinically defined full population or in, eg, biomarker‐defined subpopulations …